Pancreatic Cancer Research

ResearcherTallaght University HospitalActive in the last 2 years

Ray McDermott

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8952-4315; OpenAlex author ID A5006249276. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 3, last author 3)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
31
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: none · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper, 1 trial · 2025: none · 2026: 1 paper

Papers 12

  1. Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in adv… First author DOI 10.1186/s12885-025-14512-2↗
  2. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Co-author DOI 10.3389/fmed.2024.1369136↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Der… Co-author DOI 10.3390/life13030608↗
  5. Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. Co-author DOI 10.3390/ijms21030962↗
  6. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.07.039↗
  7. Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000870↗
  8. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗
  9. Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. Last author DOI 10.1007/s12029-012-9419-9↗
  10. Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results. First author DOI 10.1093/annonc/mdt296↗
  11. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. Last author DOI 10.1177/030089161309900413↗
  12. Aberrations and therapeutics involving the developmental pathway Hedgehog in pancreatic cancer. First author DOI 10.1016/b978-0-12-394622-5.00016-x↗

Trials 2

  1. Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial) Principal investigator NCT06149546↗
  2. Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT00962312↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oonagh M. Griffin · 1 shared paper, 1 shared trial, 2019–2024 · strength 0.80
  2. Kevin C. Conlon · 5 shared papers, 2013–2023 · strength 0.43
  3. Anna Linehan · 1 shared paper, 2024 · strength 0.31
  4. Grainne Mary O'Kane · 1 shared paper, 2024 · strength 0.31
  5. Derek Gerard Power · 2 shared papers, 2013–2026 · strength 0.27
  6. Sandra Roche · 2 shared papers, 2020–2023 · strength 0.23
  7. Fiona O’Neill · 2 shared papers, 2020–2023 · strength 0.23
  8. Robert M. Straubinger · 2 shared papers, 2020–2023 · strength 0.23
  9. Martin M. Clynes · 2 shared papers, 2020–2023 · strength 0.23
  10. David J. Easty · 1 shared paper, 2026 · strength 0.23
  11. Patrick Glyn Morris · 1 shared paper, 2026 · strength 0.23
  12. Bryan T. Hennessy · 1 shared paper, 2026 · strength 0.23
  13. Adrian Gerard Murphy · 1 shared paper, 2026 · strength 0.23
  14. Min Yuen Teo · 3 shared papers, 2013 · strength 0.16
  15. Taylor J. Allen-Coyle · 1 shared paper, 2023 · strength 0.14
  16. Finbarr O’Sullivan · 1 shared paper, 2023 · strength 0.14
  17. Paula Meleady · 1 shared paper, 2023 · strength 0.14
  18. Fergal C. Kelleher · 2 shared papers, 2012–2017 · strength 0.14
  19. Rozana Abdul Rahman · 1 shared paper, 2020 · strength 0.09
  20. Paul F. Ridgway · 2 shared papers, 2013 · strength 0.08
  21. Hazel O’Sullivan · 1 shared paper, 2017 · strength 0.08
  22. Andrés Jesús Muñoz Martín · 1 shared paper, 2016 · strength 0.04
  23. Satvinder Mudan · 1 shared paper, 2016 · strength 0.04
  24. Justin Stebbing · 1 shared paper, 2016 · strength 0.04
  25. Demetris Papamichael · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.